In a report released today, Michael Petusky from Barrington maintained a Buy rating on DENTSPLY SIRONA, with a price target of $21.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Petusky has given his Buy rating due to a combination of factors including the recent appointment of Daniel Scavilla as the new CEO of DENTSPLY SIRONA. Scavilla’s extensive experience, particularly his leadership role at Globus Medical and his long tenure at Johnson & Johnson, is seen as a positive change that could enhance the company’s commercial, operational, and financial performance.
Additionally, the company has preannounced solid second-quarter results, with expected revenue and adjusted EPS surpassing previous estimates. The reaffirmation of the financial guidance for FY/25 further supports confidence in the company’s future performance. These elements, combined with a strategic price target of $21 based on an 8.5x multiple to the FY/25 adjusted EBITDA estimate, underpin the OUTPERFORM rating for XRAY shares.
According to TipRanks, Petusky is a 3-star analyst with an average return of 0.9% and a 43.30% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Option Care Health, DENTSPLY SIRONA, and Haemonetics.